Critical Outcome Technologies Files Revised 2013 Annual Financial Statements Due to Clerical Error

Critical Outcome Technologies Files Revised 2013 Annual Financial Statements Due to Clerical Error

ID: 293624

(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 09/04/13 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation") announced today that it has filed revised financial statements for its fiscal year ending April 30, 2013. The financial statements previously filed on SEDAR on August 27, 2013, contained clerical errors made in preparing the electronic filing that resulted in a filing that did not conform to the financial statements approved by the Board. These errors had no effect on the earnings or assets previously reported and did not affect the results reported by press release or the disclosures set out in the Company's Management Discussion and Analysis as previously filed.

Details concerning these revisions can be found on SEDAR at or the Company's website at .

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

Follow (at)CriticalOutcome on Twitter at .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157



Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061




Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  NIH Awards HTG Molecular Additional $1.01M to Continue Development of Targeted Sequencing Product Concept Theravance Announces Positive Results From Phase 2b Study 0091 With Its LAMA Candidate, TD-4208, for the Treatment of COPD
Bereitgestellt von Benutzer: Marketwired
Datum: 04.09.2013 - 20:05 Uhr
Sprache: Deutsch
News-ID 293624
Anzahl Zeichen: 0

contact information:
Town:

LONDON, ONTARIO



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 243 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies Files Revised 2013 Annual Financial Statements Due to Clerical Error"
steht unter der journalistisch-redaktionellen Verantwortung von

Critical Outcome Technologies Inc. (COTI) (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Critical Outcome Technologies Closes Financing ...

LONDON, ONTARIO -- (Marketwired) -- 12/22/14 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Corporation") the biopharmaceutical company that uses machine learning to rapidly develop targe ...

Alle Meldungen von Critical Outcome Technologies Inc. (COTI)



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z